X0306 4 2017-11-25 0 0001594864 Juno Therapeutics, Inc. JUNO 0001723629 LEE ANN L. C/O 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 0 1 0 0 EVP, Technical Operations Common Stock 2017-11-25 4 A 0 35004 0.00 A 35004 D Common Stock 2017-11-25 4 A 0 35000 0.00 A 70004 D Stock Opton (Right to Buy) 62.85 2017-11-25 4 A 0 152900 0.00 A 2027-11-24 Common Stock 152900 152900 D Represents a restricted stock award ("RSA") granted pursuant to the 2014 Equity Incentive Plan. 50% of the shares subject to the RSA shall vest on each anniversary of November 25, 2017. Represents a RSA granted pursuant to the 2014 Equity Incentive Plan. The RSA will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date: Up to 21,000 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the "FDA") of JCAR017 in any indication within certain designated timeframes (the "JCAR017 Milestone"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement. Up to 9,000 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes. 25% of the shares subject to the option shall vest and become exercisable on November 25, 2018 and 1/48th of the shares subject to the option shall vest and become exercisable monthly thereafter. /s/ Zachary D. Hale, attorney-in-fact 2017-11-28